FONDATION-IPSEN
26.11.2015 15:01:22 CET | Business Wire | Press release
The 20th annual Longevity Prize of the Fondation IPSEN has been awarded to Steven N. Austad (University of Alabama at Birmingham, USA ), in recognition of his outstanding leadership in the domain of the comparative biology of aging (especially the study of species resisting to aging), by an international jury led by Thomas Kirkwood (Newcastle University, Newcastle, UK ). He received the €20,000 prize on November 21st , 2015 at the Gerontology Society of America (GSA) in Orlando, USA where he presented an outstanding lecture.
“Evolution is smarter than you are.” That quote from biochemist Leslie Orgel forms the basis for looking to nature for creative ways to slow the damaging processes of aging. Ironically, the laboratory animals scientists generally use to try to understand aging processes – and learn how to retard them – are demonstrably unsuccessful at combating these degenerative processes. It doesn’t take long to determine whether the researchers have succeeded in lengthening their health- and lifespan. On the other hand, methods for making an animal that normally lives 2 years survive to age 4, may not be relevant for an animal – humans – that already lives 80 years or more. A complementary approach is to scour nature for animals that nature has already given the tools to combat aging successfully and to try to discover what those tools are and how they work. Animals that are more successful than humans at resisting aging processes are abundant on earth. The research of Steven N. Austad has employed a number of such species over the years.
Dr. Austad is Distinguished Professor and Chair of the Department of Biology at the University of Alabama at Birmingham and also Scientific Director of the American Federation for Aging Research. After receiving his PhD degree from Purdue University, he accepted his first faculty position as Assistant Professor at Harvard University in 1986. He subsequently moved to the University of Idaho where he became full professor in 1997. In 2004, he joined the Barshop Institute for Longevity & Aging Studies at the University of Texas Health Science Center San Antonio in San Antonio, Texas before moving to his current position in 2014. His research encompasses many aspects of the biology of aging from the molecular to the population level. His research specialty is the identification and study of nontraditional species – particularly exceptionally long-lived species – for insight into processes of slow aging. Dr. Austad’s research has won multiple previous awards, including the Geron Corporation-Samuel Goldstein Distinguished Publication Award, the Nathan A. Shock Award, the Robert W. Kleemeier Award, the Purdue Outstanding Alumnus Award, and the Irving S. Wright Award of Distinction.
Previous laureates of the Longevity Prize
Founded in 1996,
the Longevity Prize of the Fondation IPSEN has been awarded to renowned
specialists: Caleb E. Finch (Los Angeles, 1996)
, Vaino Kannisto (Lisboa,
1997),
Roy L. Walford (Los Angeles, 1998),
John Morley (St
Louis,1999),
Paul & Margret Baltes (Berlin, 2000),
Justin
Congdon (Aiken, 2001),
George Martin (Seattle, 2002),
James
Vaupel (Rostock, 2003),
Linda Partridge (London, 2004),
Sir
Michael Marmot (London, 2005),
Cynthia Kenyon (San Francisco,
2006),
David Barker (Southampton, 2007),
Gerald McLearn
(University Park, 2008
), Jacques Vallin (Paris, 2009),
Judith
Campisi (Novato, 2010), Tom Kirkwood (Newcastle, 2011),
Linda
Fried (New York, 2012),
Gary Ruvkun (Boston, 2013),
Luigi
Ferrucci (Baltimore, 2014).
The jury members of the Longevity Prize
Thomas Kirkwood (Newcastle
University, Newcastle, UK
), President
Judith Campisi (Buck
Institute for Research on Ageing, Novato, USA
), Eileen Crimmins (University
of Southern California, Los Angeles, USA
), Caleb Finch (University
of Southern California, Los Angeles, USA
), Bernard Jeune (Odense
Universitet, Odense, Denmark
), George Martin (University of
Washington, Seattle, USA
), Jean-Marie Robine (INSERM, Démographie
et Santé, Montpellier, France
), Bruno Vellas (Hôpital Purpan,
Toulouse, France
) and a Fondation IPSEN representative.
About the Fondation IPSEN
Established in 1983 under the
aegis of the Fondation de France, the mission of the Fondation IPSEN is
to contribute to the development and dissemination of scientific
knowledge. The long-standing action of the Fondation IPSEN aims at
fostering the interaction between researchers and clinical
practitioners, which is essential due to the extreme specialization of
these professions. The ambition of the Fondation IPSEN is to initiate a
reflection about the major scientific issues of the forthcoming years.
It has developed an important international network of scientific
experts who meet regularly at meetings known as Colloques Médecine et
Recherche
, dedicated to six main themes: Alzheimer's disease,
neurosciences, longevity, endocrinology, the vascular system and cancer
science. Moreover the Fondation IPSEN has started since 2007 several
meetings in partnership with the Salk Institute, the Karolinska
Institutet, the Massachusetts General Hospital, the Days of Molecular
Medicine Global Foundation as well as with the science journals Nature
,
Cell
and Science
. The Fondation IPSEN produced several
hundred publications; more than 250 scientists and biomedical
researchers have been awarded prizes and research grants.
www.fondation-ipsen.org
View source version on businesswire.com: http://www.businesswire.com/news/home/20151126005262/en/
Contact:
Image Sept
Isabelle de Segonzac, Tel: +33 (0)1 53 70 74 70
Email:
isegonzac@image7.fr
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Responding to Customer Demand, Starlink High-Speed Connectivity Now Available as an Aftermarket Option on the Cessna Citation Ascend; 560XL Series Achieves EASA Certification21.4.2026 14:00:00 CEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced at AERO Friedrichshafen the availability of Starlink highspeed connectivity as an aftermarket upgrade for the Cessna Citation Ascend, the newest aircraft in the bestselling Cessna Citation 560XL series, following the Federal Aviation Administration’s issuance of AeroMech’s Supplemental Type Certificate (STC). In addition, the Cessna Citation 560 XL fleet — including the XLS Gen 2, XLS+, XLS and Excel — has received European Union Aviation Safety Agency (EASA) certification for Starlink installation at Textron Aviation’s European service centers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420017406/en/ Responding to customer demand, Starlink high-speed connectivity now available as an Aftermarket option on the Cessna Citation Ascend; 560XL series achieves EASA certification AeroMech’s STC utilizes Starlink’s high-speed internet technology connec
Moody’s Advances Decision-Grade Credit Intelligence Across Enterprise AI Workflows, Powered by Microsoft 365 Copilot21.4.2026 14:00:00 CEST | Press release
Moody’s decision-grade intelligence now available directly in the AI-powered tools where market participants work Moody’s Corporation (NYSE: MCO) today announced the next phase of its strategic partnership with Microsoft, integrating Moody’s decision-grade intelligence directly into Microsoft AI solutions. The milestone expands the collaboration from co-innovation to scaled, workflow-embedded distribution of Moody’s decision-grade intelligence across the enterprise environments where its customers work every day. “For over 115 years, Moody’s has served as the intelligence layer that financial professionals turn to when making consequential decisions,” said Rob Fauber, President and Chief Executive Officer of Moody’s. “By embedding that intelligence directly into Microsoft’s AI solutions at enterprise scale, we’re making decision-grade analysis available not just to specialists, but to every person across an organization who needs it.” The integrations operate across two channels. Using
Redslim expands its global footprint into Latin America21.4.2026 14:00:00 CEST | Press release
Redslim, a specialist in end-to-end data management solutions and an Astorg portfolio company, today announced its expansion into the Latin America (LATAM) region, marking the next step in its growth strategy to support multinational brands and retailers across every major market. Following its recent expansion into APAC, this move reinforces Redslim’s momentum in building a truly global presence, reflecting growing demands from international clients for a trusted partner delivering reliable and AI-ready data and insights at scale. The expansion includes the appointment of Alejandro Merlo as Regional Director and Javier Gonzalez as Regional Manager for the region. Latin America represents a strong growth opportunity for global consumer brands, but also one of the most complex data environments. Rapid digital adoption and shifting consumer behaviours are driving demand for reliable market intelligence, while fragmented retailer structures and country-specific data landscapes make consis
Adtran’s SDG router portfolio receives FCC conditional approval, supporting ongoing broadband expansion21.4.2026 14:00:00 CEST | Press release
News summary: FCC approval exempts Adtran’s SDG router portfolio from Covered List restrictions through October 1, 2027 Decision enables uninterrupted shipments, authorizations and deployments across current and next-generation SDG platforms Regulatory clarity supports long-term SDG investment and rollout planning Adtran today announced that its service delivery gateway (SDG) carrier-grade router portfolio has received conditional approval from the FCC’s Public Safety and Homeland Security Bureau, formally exempting the platforms from FCC Covered List restrictions through October 1, 2027. The decision places Adtran among the first router manufacturers to achieve this designation under the FCC’s national security review process. By ensuring continued access to Adtran’s SDG technology, the approval enables service providers to maintain deployment momentum, reduce operational risk and invest confidently in the long-term expansion of broadband networks while navigating evolving regulatory
Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs21.4.2026 14:00:00 CEST | Press release
Partnership enables timely access to botensilimab plus balstilimab through France’s government-reimbursed Autorisation d’Accès Compassionnel (AAC) pathway and paid named-patient programs (NPP) in select countries Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, and BAP Pharma, a global medicines access and clinical trial supply company, today announced the exclusive appointment of BAP Pharma as Agenus’ global partner for botensilimab (BOT) plus balstilimab (BAL) authorized global access programs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421146539/en/ The partnership supports compliant, patient-focused access to BOT+BAL through authorized pathways where permitted by local regulations. Effective immediately, BAP Pharma will serve as Agenus’ exclusive partner for the coordination of BOT+BAL global access program operations, including program requests, case coordination, distribution logistics, and re
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
